Clinical trial

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01503229

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Abiraterone Acetate Normalized identity: abiraterone acetateView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Laboratory Biomarker Analysis Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Pharmacological Study Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Prednisone Normalized identity: prednisoneView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-12-01

PhasePHASE2

Conditions

Hormone-Resistant Prostate Cancerverified · MONDO: hormone-resistant prostate carcinoma

Metastatic Prostate Carcinomaverified · MONDO: metastatic prostate carcinoma

Recurrent Prostate Carcinomaunresolved

Stage IV Prostate Adenocarcinomaunresolved

Interventions

Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate

Laboratory Biomarker AnalysisOTHER

Pharmacological StudyOTHER

PrednisoneDRUG · verified · RxNorm: prednisone

Sponsors & collaborators

University of Washingtonlead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01503229 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.